The medical treatment of the actinic keratosis and the skin tumours: photodynamic therapy (PDT)

Though the experimental studies on the activation of “photodynamic” medications was only published 1999, the FDA approved the use of the ALA (Aminolevulinic) in the dermatologic field. In substance, the PDT by using photosensitive medicines at a topical level (ALA and MAL), a luminous source with an appropriate wavelength for their activation, set the formation of protoporphyrin IX and when it returns to its native state, reacts with molecular oxygen and forms reactive species like the “singoletto” oxygen. The formation of this substance is to the base of the fall events that may lead to the destruction of the cellule through the: